Posting of Circular & Notice of GM

RNS Number : 8624O

Evgen Pharma PLC

12 February 2021

 

Evgen Pharma plc

("Evgen Pharma" or "the Company")

Posting of Circular

and

Notice of General Meeting

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that further to its announcement of the proposed Fundraising on 2 February 2021 (the " Placing Announcement "), a Circular, including the notice of General Meeting, a Form of Proxy and (where applicable) an Open Offer Application Form are today being posted to shareholders. The General Meeting will be held at 10:00 a.m. on 3 March 2021.  

 

In light of the current restrictions in place with respect to the COVID-19 pandemic and, in particular, the UK Government's response (including guidance on working from home in place at the date of this notice), the Company's Board of Directors have concluded that the General Meeting will be held as a closed meeting. The Company will make arrangements such that the legal requirements to hold the General Meeting can be satisfied through the electronic attendance of the minimum number of shareholders, drawn from members of the Board. No other shareholder will be able to attend the General Meeting and are, instead, requested to complete the Form of Proxy, appointing the chairman of the meeting, rather than a third party, as their proxy by the relevant time.  

 

Copies of the Circular and Form of Proxy will be made available on the Company's website www.evgen.com .

 

Capitalised terms used in this announcement shall have the same meanings as the definitions in the Placing Announcement   unless otherwise defined herein .

Enquiries:

Evgen Pharma plc Barry Clare, Chairman Dr Huw Jones, CEO Richard Moulson, CFO	Via Walbrook
finnCap Geoff Nash / Teddy Whiley (Corporate Finance) Alice Lane / Sunila de Silva (ECM) www.finncap.com	[phone]
Walbrook PR   Paul McManus/ Anna Dunphy	[phone] or  [e-mail] [phone] / [phone]

About Evgen Pharma plc  

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  

For further information, please visit:  www.evgen.com  

 

END

 

 

NOGTBMFTMTJBBPB